Publications by authors named "Junling Zhuang"

To compare the efficacy and safety of gecacitinib (also known as jaktinib) with hydroxyurea (HU) in treating myelofibrosis (MF) patients. In this multicenter, randomized phase 3 trial (ZGJAK016), intermediate- or high-risk primarily JAK inhibitor naïve MF patients were assigned in a 2:1 ratio to receive either gecacitinib (100 mg twice a day, BID) or HU (500 mg BID). The primary endpoint was the proportion of patients with ≥35% reduction in spleen volume (SVR35) from baseline at week 24.

View Article and Find Full Text PDF

The RVd therapy, combining lenalidomide, bortezomib, and dexamethasone, is a mainstay treatment for multiple myeloma. A multiple myeloma patient developed pure red cell aplasia (PRCA) following RVd treatment, despite the absence of common PRCA triggers. In vitro analyses reveal lenalidomide as a pivotal disruptor of erythropoiesis.

View Article and Find Full Text PDF

Background: Broad T cell phenotypic alterations and potential dysfunctions were prominent in COVID-19. There are few and inconclusive data about the role of immune checkpoints for T cell exhaustion/activation during SARS-CoV-2 infection in multiple myeloma (MM) patients.

Methods: We tested T cell subsets and immune checkpoints in 177 MM patients with COVID-19, as well as in 32 healthy infected controls and 42 uninfected MM patients.

View Article and Find Full Text PDF
Article Synopsis
  • The study compared the effectiveness of two imaging methods, [Ga]pentixather PET/CT and [Ga]pentixafor PET/CT, in detecting multiple myeloma in newly diagnosed patients.
  • Results showed that [Ga]pentixather had a higher detection rate and better lesion uptake values than [Ga]pentixafor, suggesting it may be more effective for assessing tumor load.
  • Additionally, both PET scans indicated that higher tumor burden was associated with more advanced stages of the disease according to the Durie-Salmon Staging system.
View Article and Find Full Text PDF

Apart from bone marrow involvement, extranodal involvement of follicular lymphoma (FL) is rare. Gynecologic FL is seldom reported, among which the vagina is the rarest involved site. No vaginal involvement in advanced-staged FL was reported before.

View Article and Find Full Text PDF

Objective: To evaluate the efficacy and prognosis of percutaneous vertebroplasty/kyphoplasty (PVP/PKP) in patients with newly diagnosed multiple myeloma (NDMM).

Methods: Clinical data of NDMM patients who underwent PVP/PKP during front-line regimen at Peking Union Medical College Hospital from January 1, 2003, to June 30, 2023, were analyzed. Patients with comparable bone diseases not receiving orthopedic surgery were selected as controls.

View Article and Find Full Text PDF
Article Synopsis
  • A significant spike in SARS-CoV-2 Omicron variant infections occurred in China at the end of 2022, severely affecting multiple myeloma (MM) patients and leading to increased mortality rates.
  • A study involving 218 MM patients and 73 healthy controls assessed immune responses over time, revealing that factors like older age, active disease, and lack of vaccination significantly raised the risk of hospitalization after infection.
  • Findings indicate that while T-cell responses remain robust, humoral immunity deteriorates quickly—especially among older and unvaccinated patients—highlighting the need for additional boosters for high-risk MM patients after 14-16 weeks post-infection.
View Article and Find Full Text PDF

Background: Myc rearrangement (Myc-R) is a controversial factor linked to adverse outcomes in newly diagnosed multiple myeloma (NDMM).

Aims: This study aimed to evaluate the impact of Myc-R on the prognosis of NDMM patients and its role in risk stratification compared with traditional high-risk cytogenetic abnormalities (HRCAs).

Materials & Methods: A total of 417 NDMM patients enrolled from May 2009 to September 2022 were included.

View Article and Find Full Text PDF

Objective: To evaluate the effectiveness, safety, and convenience of in-class transition (iCT) from intravenous bortezomib-based induction to ixazomib-based oral regimens.

Methods: This retrospective real-world study was conducted in 16 Chinese hospitals between October 2017 and April 2023 and analyzed newly diagnosed (NDMM) and first-line relapsed multiple myeloma (FRMM) patients who attained at least a partial response from bortezomib-based induction therapy, followed by an ixazomib-based oral regimen for 2 year or until disease progression or intolerable toxicity.

Results: The study enrolled 199 patients, median age: 63 years old, male 55.

View Article and Find Full Text PDF

An 83-year-old woman with newly diagnosed multiple myeloma (MM) was enrolled in our 68 Ga-pentixather and 68 Ga-pentixafor PET/CT trial for evaluation of tumor burden. 68 Ga-pentixather PET/CT detected more focal bone lesions, and the uptake levels of focal bone lesions on 68 Ga-pentixather PET/CT were higher than those on 68 Ga-pentixafor PET/CT. This suggests that 68 Ga-pentixather PET/CT may be an alternative imaging modality and more sensitive in detecting MM lesions than 68 Ga-pentixafor PET/CT.

View Article and Find Full Text PDF

Introduction: The definition of primary plasma cell leukemia (pPCL) has been revised from ≥20% to ≥5% circulating plasma cells (CPC). However, the precise prognosis associated with CPC remains controversial. This study aimed to investigate prognostic biomarkers for myeloma patients based on CPC presence.

View Article and Find Full Text PDF

Jaktinib, a novel JAK and ACVR1 inhibitor, has exhibited promising results in treating patients with myelofibrosis (MF). ZGJAK002 is a Phase 2 trial aimed to assess the efficacy and safety of jaktinib 100 mg BID (N = 66) and 200 mg QD (N = 52) in JAK inhibitor-naive patients with intermediate- or high-risk MF. We herein present the long-term data with a median follow-up of 30.

View Article and Find Full Text PDF
Article Synopsis
  • This study looked at how well two treatments (IRd and IDd) work for older, frail patients with a type of cancer called multiple myeloma.
  • 120 patients aged 65 and older participated and received different combinations of medicines to see which worked better and was safer.
  • Results showed that both treatments helped many patients, but there were different rates of side effects and how long patients stayed healthy after treatment.
View Article and Find Full Text PDF

Maintenance treatment is a pivotal part in the whole process management of multiple myeloma (MM), which further deepens response and improves survival. However, evidence of maintenance in non-transplant MM patients is inadequate in real-world practice. Here, we retrospectively analyzed the efficacy and survival of 375 non-transplant MM patients from 11 centers between 2010 and 2021 in north China.

View Article and Find Full Text PDF

Introduction: Genetic landscape, disease characteristics, and clinical outcomes of young adults with myeloproliferative neoplasms (MPNs) were reported. However, data on patient-reported outcomes (PROs) in young adults with MPNs were rare.

Methods: We conducted a multicenter, cross-sectional study to compare the PROs in respondents with thrombocythemia (ET), polycythemia vera (PV), and myelofibrosis (MF) by age at survey, including the young group (18-40 years), middle-aged group (41-60 years), and elderly group (>60 years).

View Article and Find Full Text PDF
Article Synopsis
  • - Bone disease is a frequent issue for patients with multiple myeloma, leading to complications like bone pain, fractures, and spinal cord problems, which negatively affect their quality of life and survival! - The development of myeloma bone disease involves an imbalance in bone remodeling, with increased activity of bone-resorbing cells (osteoclasts) and decreased activity of bone-forming cells (osteoblasts), influenced by various factors like RANKL and DKK-1! - Current treatments for myeloma bone disease include bisphosphonates and denosumab, with the latter being especially suitable for patients with kidney issues; however, effective cancer therapy remains crucial for managing bone health!
View Article and Find Full Text PDF

Background: The use of proteasome inhibitors (PIs), new immune modulators (IMiDs), and other new drugs, as well as high-dose chemotherapy combined with autologous stem cell transplantation has considerably improved the survival of young patients with multiple myeloma (MM). However, the improvement in survival among elderly patients remains insufficient. Optimal treatment recommendation models for elderly patients with MM have not been developed especially there are quite few study in the real world.

View Article and Find Full Text PDF

Myelofibrosis (MF) is associated with several constitutional symptoms. Currently, there are few therapeutic options for MF. Jaktinib, a novel, small-molecule inhibitor of JAK, is currently being studied for its potential to treat MF.

View Article and Find Full Text PDF

Objectives: The prognosis for adults with relapsed/refractory (R/R) B-cell precursor acute lymphoblastic leukemia (BCP-ALL) is poor. Blinatumomab is a CD3/CD19-directed BiTE® (bispecific T-cell engager) molecule approved globally for the treatment of BCP-ALL in adults and children. This multicenter open-label single-arm China registrational study evaluated the safety, efficacy, and pharmacokinetics of blinatumomab in Chinese adults with Philadelphia chromosome-negative (Ph-) R/R BCP-ALL (NCT03476239).

View Article and Find Full Text PDF

Objective: To use machine learning methods to explore overall survival (OS)-related prognostic factors in elderly multiple myeloma (MM) patients.

Methods: Data were cleaned and imputed using simple imputation methods. Two data resampling methods were implemented to facilitate model building and cross validation.

View Article and Find Full Text PDF